

Jeffrey S Barrett

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7602090/jeffrey-s-barrett-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

645
citations

15
h-index

24
g-index

47
ext. papers

768
ext. citations

4.1
avg, IF

3.83
L-index

#	Paper	IF	Citations
44	Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3462-3480	3.8	0
43	Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. <i>Journal of Clinical Pharmacology</i> , 2021 , 61 Suppl 1, S52-S59	2.9	0
42	Status Toward the Implementation of Precision Dosing in Children. <i>Journal of Clinical Pharmacology</i> , 2021 , 61 Suppl 1, S36-S51	2.9	2
41	Asking More of Our EHR Systems to Improve Outcomes for Pediatric Patients. <i>Frontiers in Pharmacology</i> , 2020 , 11, 253	5.6	1
40	Serum amoxicillin levels in young infants (0-59 days) with sepsis treated with oral amoxicillin. <i>Archives of Disease in Childhood</i> , 2020 , 105, 1208-1214	2.2	4
39	Time to Expect More From Pharmacometrics. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1129-1131	3.1	2
38	Perspective on Data-Sharing Requirements for the Necessary Evolution of Drug Development. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 688-690	2.9	0
37	Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 29-39	6.1	7
36	Real-World Data: An Unrealized Opportunity in Global Health?. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 57-59	6.1	1
35	A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. <i>AAPS Journal</i> , 2019 , 21, 81	3.7	4
34	Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 419-433	6.1	22
33	Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 442-452	4.5	12
32	Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 601-611	6.2	18
31	Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. <i>Pediatric Research</i> , 2017 , 81, 692-711	3.2	59
30	Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults. <i>JCI Insight</i> , 2017 , 2,	9.9	11
29	Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. <i>Journal of Translational Medicine</i> , 2016 , 14, 148	8.5	13
28	Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 1326-1334	2.9	42

27	Paediatric models in motion: requirements for model-based decision support at the bedside. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 85-96	3.8	18
26	Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review. <i>JAMA Pediatrics</i> , 2015 , 169, 678-85	8.3	53
25	Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 854-65	2.9	12
24	Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. <i>Pharmacotherapy</i> , 2015 , 35, 670-80	5.8	29
23	Adjuvant therapies for HIV-associated neurocognitive disorders. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 938-52	5.3	18
22	Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients. <i>AAPS Journal</i> , 2013 , 15, 775-86	3.7	13
21	PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 725-8	1.7	4
20	A Modeling and Simulations Framework to Support Global Regulatory Strategies for Pediatric Drug Development Programs. <i>Therapeutic Innovation and Regulatory Science</i> , 2013 , 47, 550-556	1.2	4
19	GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies. <i>Clinical Pharmacology in Drug Development</i> , 2013 , 2, 379-86	2.3	8
18	Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 99-107	3.2	30
17	Prescribing habits and caregiver satisfaction with resources for dosing children: rationale for more informative dosing guidance. <i>BMC Pediatrics</i> , 2011 , 11, 25	2.6	11
16	Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience. <i>Blood</i> , 2011 , 118, 2580-2580	2.2	2
15	The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 889-904	2.9	53
14	Population Pharmacokinetics of Enoxaparin in Children at Risk for Symptomatic Thromboembolism.. <i>Blood</i> , 2009 , 114, 1071-1071	2.2	1
13	Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. <i>BMC Medical Informatics and Decision Making</i> , 2008 , 8, 6	3.6	48
12	A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation. <i>Computer Methods and Programs in Biomedicine</i> , 2008 , 90, 240-50	6.9	8
11	Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 787-92	2.9	2
10	Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 632-49	2.9	62

9	The role of quantitative pharmacology in an academic translational research environment. <i>AAPS Journal</i> , 2008 , 10, 9-14	3.7	5
8	Key performance indicators for the assessment of pediatric pharmacotherapeutic guidance. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2008 , 13, 141-55	1.6	5
7	Model-based drug development applied to oncology. <i>Expert Opinion on Drug Discovery</i> , 2007 , 2, 185-209	6.2	19
6	Facilitating compound progression of antiretroviral agents via modeling and simulation. <i>Journal of NeuroImmune Pharmacology</i> , 2007 , 2, 58-71	6.9	4
5	Bioequivalence of Biologics 2006 , 189-208		1
4	Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 591-625	6.2	20
3	Pharmacodynamic Properties of the Low Molecular Weight Heparin, Tinzaparin: Effect of Molecular Weight Distribution on Plasma Tissue Factor Pathway Inhibitor in Healthy Human Subjects. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 727-734	2.9	16
2	Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies	23-37	
1	Model-Independent and Model-Based Methods to Assess Drug-Drug Interactions for Therapeutic Proteins		1